Sanofi India Limited (NSE:SANOFI)

Market Cap	72.89B -46.0%
Revenue (ttm)	17.74B -2.4%
Net Income	3.10B -21.8%
EPS	134.52 -21.8%
Shares Out	n/a
PE Ratio	23.53
Forward PE	17.94
Dividend	123.00 (3.90%)
Ex-Dividend Date	Apr 22, 2026

Volume	53,537
Average Volume	29,696
Open	3,193.00
Previous Close	3,191.00
Day's Range	3,157.00 - 3,218.50
52-Week Range	3,157.50 - 6,410.00
Beta	0.23
RSI	27.64
Earnings Date	Apr 28, 2026

About Sanofi India

Sanofi India Limited manufactures and trades in drugs and pharmaceutical products in India, Singapore and internationally. The company offers pharmaceutical products in various therapeutic areas, such as diabetes, cardiology, anti-infectives, and central nervous system under the Lantus, Toujeo, Soliqua, Clexane, Amaryl, Cardace, Lasix, Lasilactone, Glimepiride, Cetapin, Targocid, Frisium, Targocio, Combiflam, DePura, Allegra, Baralgan, BUSCOGAST, Dulcoflex, Enterogermina, Novalgin, and Avil brands through independent distributors. It also expor...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1956
• Employees: 1,097
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SANOFI

Financial Performance

In 2025, Sanofi India's revenue was 18.37 billion, a decrease of -8.73% compared to the previous year's 20.13 billion. Earnings were 3.27 billion, a decrease of -20.99%.